US6225289B1
(en)
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
PT1154790E
(pt)
*
|
1999-02-26 |
2005-03-31 |
Chiron Srl |
Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
BRPI0010612B8
(pt)
|
1999-04-19 |
2021-05-25 |
Smithkline Beecham Biologicals S A |
vacinas
|
AU781469B2
(en)
*
|
1999-05-13 |
2005-05-26 |
Wyeth Holdings Corporation |
Adjuvant combination formulations
|
GB9921146D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
CA2721011A1
(en)
|
1999-10-22 |
2001-05-03 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
ATE346925T1
(de)
|
2000-05-10 |
2006-12-15 |
Sanofi Pasteur Ltd |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
ATE534401T1
(de)
|
2000-10-18 |
2011-12-15 |
Glaxosmithkline Biolog Sa |
Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
US20040241094A1
(en)
*
|
2001-09-13 |
2004-12-02 |
Hesson Chung |
Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
|
EP1547607A4
(en)
*
|
2002-08-02 |
2008-11-26 |
Dainippon Sumitomo Pharma Co |
PREPARATION OF A COMPONENT OF BACTERIA CELL WALL SKELETON
|
PL376792A1
(pl)
|
2002-10-23 |
2006-01-09 |
Glaxosmithkline Biologicals S.A. |
Sposoby szczepienia przeciwko malarii
|
GB0411411D0
(en)
*
|
2004-05-21 |
2004-06-23 |
Glaxosmithkline Biolog Sa |
Vaccines
|
JP2008500984A
(ja)
|
2004-05-28 |
2008-01-17 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ヴィロソームとサポニンアジュバントを含むワクチン組成物
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1861120B1
(en)
|
2005-03-23 |
2016-05-25 |
GlaxoSmithKline Biologicals S.A. |
Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
ES2792398T3
(es)
*
|
2005-11-04 |
2020-11-11 |
Seqirus Uk Ltd |
Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
MY148141A
(en)
|
2005-12-22 |
2013-03-15 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3141261A1
(en)
|
2006-03-30 |
2017-03-15 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
PL2043682T3
(pl)
|
2006-07-17 |
2014-09-30 |
Glaxosmithkline Biologicals Sa |
Szczepionka przeciw grypie
|
NZ574239A
(en)
|
2006-07-18 |
2011-12-22 |
Glaxosmithkline Biolog Sa |
Hybrid fusion proteins for malaria vaccines
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
TR201807756T4
(tr)
|
2006-09-26 |
2018-06-21 |
Infectious Disease Res Inst |
Sentetik adjuvan içeren aşı bileşimi.
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
CA2668405C
(en)
|
2006-11-03 |
2015-05-05 |
Schering-Plough Ltd. |
Canine lyme disease vaccine
|
BRPI0808553A2
(pt)
|
2007-03-02 |
2014-08-19 |
Glaxosmithkline Biolog Sa |
Métodos para elevar uma resposta imune contra um patógeno, para estimar a produção de células t cd4+ e/ou cd8+ e/ou anticorpos específicos de patógeno em mamíferos e para estimular uma resposta imune em um mamífero, composição de vacina, uso da mesma, e, kit
|
PE20090146A1
(es)
|
2007-04-20 |
2009-03-23 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica contra el virus influenza
|
EP2167120A2
(en)
|
2007-06-26 |
2010-03-31 |
GlaxoSmithKline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
AP2010005166A0
(en)
|
2007-08-13 |
2010-02-28 |
Glaxosmithkline Biolog Sa |
Vaccines
|
PT2227483T
(pt)
|
2007-12-19 |
2017-06-21 |
Henry M Jackson Found Advancement Military Medicine Inc |
Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
JP5722782B2
(ja)
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
DK2396032T3
(en)
|
2009-02-10 |
2016-12-19 |
Seqirus Uk Ltd |
Influenza vaccines with reduced amounts of squalene
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
MX2011012836A
(es)
|
2009-06-05 |
2012-04-20 |
Infectious Disease Res Inst |
Adyuvantes sinteticos de glucopiranosil-lipido.
|
EP3020412B1
(en)
|
2009-06-16 |
2017-10-11 |
The Regents of the University of Michigan |
An immunogenic composition comprising nanoemulsion inactivated rsv
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
DE102009056883B4
(de)
*
|
2009-12-03 |
2012-08-16 |
Novartis Ag |
Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
|
EP2353609A1
(en)
|
2010-02-04 |
2011-08-10 |
Sanofi Pasteur |
Immunization compositions and methods
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
SG184188A1
(en)
|
2010-03-26 |
2012-10-30 |
Glaxosmithkline Biolog Sa |
Hiv vaccine
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
SG188624A1
(en)
|
2010-09-27 |
2013-04-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2646459B1
(en)
|
2010-12-02 |
2020-01-08 |
Bionor Immuno AS |
Peptide scaffold design
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
WO2012092934A1
(en)
|
2011-01-06 |
2012-07-12 |
Bionor Immuno As |
Monomeric and multimeric immunogenic peptides
|
MX350795B
(es)
|
2011-04-08 |
2017-09-19 |
Inmune Design Corp |
Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
|
SG10201701055WA
(en)
|
2011-09-16 |
2017-03-30 |
Ucb Pharma Sa |
Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
WO2013083753A2
(en)
|
2011-12-07 |
2013-06-13 |
Institut Pasteur |
Identification of a swine parecho-like virus and applications
|
ES2729967T3
(es)
|
2012-02-07 |
2019-11-07 |
Infectious Disease Res Inst |
Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
|
ES2673556T3
(es)
|
2012-05-16 |
2018-06-22 |
Immune Design Corp. |
Vacunas para el VHS-2
|
BR112014030466A2
(pt)
|
2012-06-06 |
2017-09-12 |
Bionor Immuno As |
peptídeos derivados de proteínas virais para uso como imunógenos e reagentes de dosagem
|
PE20150356A1
(es)
|
2012-07-24 |
2015-03-20 |
Sanofi Pasteur |
Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
|
SG11201500412TA
(en)
|
2012-07-24 |
2015-02-27 |
Sanofi Pasteur |
Vaccine compositions
|
PL2912186T3
(pl)
|
2012-10-24 |
2021-06-14 |
Platelet Targeted Therapeutics Llc |
Leczenie ukierunkowane na płytki krwi
|
WO2014083194A1
(en)
|
2012-11-30 |
2014-06-05 |
Sanofi Pasteur |
Methods for inducing antibodies
|
EP3711768A1
(en)
|
2013-04-18 |
2020-09-23 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
US10208102B2
(en)
|
2013-11-01 |
2019-02-19 |
University Of Oslo |
Albumin variants and uses thereof
|
US10357554B2
(en)
|
2013-11-11 |
2019-07-23 |
The United States Of America, As Represented By The Secretary Of The Army |
AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
|
WO2015071769A2
(en)
|
2013-11-13 |
2015-05-21 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
US11452767B2
(en)
|
2013-11-15 |
2022-09-27 |
Oslo Universitetssykehus Hf |
CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
CA2931112A1
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Pan pollen immunogens and methods and uses for immune response modulation
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
KR102411781B1
(ko)
|
2013-12-31 |
2022-06-22 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
단일 바이알 백신 제형
|
CR20160369A
(es)
|
2014-01-21 |
2016-10-05 |
Immune Desing Corp |
Composiciones para uso en el tratamiento de afecciones alérgicas
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
KR101696514B1
(ko)
*
|
2014-08-18 |
2017-01-24 |
서울대학교산학협력단 |
신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
|
ES2924988T3
(es)
|
2014-10-10 |
2022-10-13 |
Univ Michigan Regents |
Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
EP3268034A4
(en)
|
2015-03-05 |
2018-11-14 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
GEP20217232B
(en)
|
2016-03-14 |
2021-03-25 |
I Oslo Universitetet |
Engineered immunoglobulins with altered fcrn binding
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
EP3471761A2
(en)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
US11498956B2
(en)
|
2016-08-23 |
2022-11-15 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
|
US11466292B2
(en)
|
2016-09-29 |
2022-10-11 |
Glaxosmithkline Biologicals Sa |
Compositions and methods of treatment
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
CA3066915A1
(en)
|
2017-06-11 |
2018-12-20 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
KR20200028395A
(ko)
|
2017-06-15 |
2020-03-16 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
US20210069319A1
(en)
|
2017-09-07 |
2021-03-11 |
University Of Oslo |
Vaccine molecules
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
CN111615397A
(zh)
|
2017-11-03 |
2020-09-01 |
武田疫苗股份有限公司 |
寨卡疫苗和免疫原性组合物及其使用方法
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
CN112638936A
(zh)
|
2018-06-12 |
2021-04-09 |
葛兰素史密丝克莱恩生物有限公司 |
腺病毒多核苷酸和多肽
|
EP3833382A1
(en)
|
2018-08-07 |
2021-06-16 |
GlaxoSmithKline Biologicals S.A. |
Processes and vaccines
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
EP3934687A1
(en)
|
2019-03-05 |
2022-01-12 |
GlaxoSmithKline Biologicals S.A. |
Hepatitis b immunisation regimen and compositions
|
KR20220125149A
(ko)
|
2019-05-25 |
2022-09-14 |
액세스 투 어드밴스드 헬스 인스티튜트 |
애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
|
US20230109142A1
(en)
|
2020-02-14 |
2023-04-06 |
Immunor As |
Corona virus vaccine
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|